European Union - English - EMA (European Medicines Agency)

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy.in adult patients, to help differentiate probable dementia with lewy bodies from alzheimer’s disease. celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bioherbicides australia pty ltd - lasiodiplodia pseudotheobromae nt039; macrophomina phaseolina nt094; neoscytalidium novaehollandiae qld 003 - capsule suspension - lasiodiplodia pseudotheobromae nt039 biological- organisum fungus active 0.0 x; macrophomina phaseolina nt094 biological- organism- fungus active 0.0 x; neoscytalidium novaehollandiae qld 003 biological-organism fungus active 0.0 x - herbicide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adama australia pty limited - lasiodiplodia pseudotheobromae nt039; macrophomina phaseolina nt094; neoscytalidium novaehollandiae qld 003 - capsule suspension - lasiodiplodia pseudotheobromae nt039 biological- organisum fungus active 0.0 x; macrophomina phaseolina nt094 biological- organism- fungus active 0.0 x; neoscytalidium novaehollandiae qld 003 biological-organism fungus active 0.0 x - herbicide

Egypt - English - EDA (Egyptian Drug Authority)

el nile. - tablet - 5 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - benserazide hydrochloride, quantity: 57 mg (equivalent: benserazide, qty 50 mg); levodopa, quantity: 200 mg - tablet, uncoated - excipient ingredients: iron oxide red; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; calcium hydrogen phosphate; mannitol; pregelatinised maize starch; docusate sodium; ethylcellulose - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg); levodopa, quantity: 100 mg - capsule, hard - excipient ingredients: mannitol; indigo carmine; iron oxide yellow; hypromellose; titanium dioxide; magnesium stearate; purified talc; gelatin; hydrogenated vegetable oil; povidone; calcium hydrogen phosphate dihydrate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; iron oxide red; ethanol absolute; potassium hydroxide; ammonia - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism. madopar hbs is indicated for patients presenting with all types of fluctuations in response (i.e. "peak dose dyskinesia" and "end of dose deterioration") and for better control of nocturnal symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 200 mg; benserazide hydrochloride, quantity: 57 mg (equivalent: benserazide, qty 50 mg) - capsule, hard - excipient ingredients: iron oxide yellow; magnesium stearate; indigo carmine; povidone; gelatin; titanium dioxide; purified talc; microcrystalline cellulose; iron oxide red - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - benserazide hydrochloride, quantity: 14.25 mg (equivalent: benserazide, qty 12.5 mg); levodopa, quantity: 50 mg - tablet, dispersible - excipient ingredients: magnesium stearate; pregelatinised maize starch; citric acid; microcrystalline cellulose - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 100 mg; benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg) - tablet, dispersible - excipient ingredients: citric acid; microcrystalline cellulose; magnesium stearate; pregelatinised maize starch - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 100 mg; benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg) - tablet, uncoated - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; docusate sodium; iron oxide red; calcium hydrogen phosphate; magnesium stearate; ethylcellulose; mannitol - parkinson's disease and parkinsonian symptoms including post- encephalitic and toxic forms, but excluding drug induced parkinsonism.